Naperville, IL -- (SBWire) -- 03/11/2015 --Reportstack, provider of premium market research reports announces the addition of Obesity - Pipeline Review, H1 2015 market report to its offering.

Obesity - Pipeline Review, H1 2015

Summary

Obesity - Pipeline Review, H1 2015, provides an overview of the Obesitys therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Obesity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Obesity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Advinus Therapeutics Ltd.
Aegis Therapeutics, LLC
Aileron Therapeutics, Inc.
Akron Molecules AG
Alize Pharma SAS
Ambrx, Inc.
Amgen Inc.
Arena Pharmaceuticals, Inc.
Arrien Pharmaceuticals, LLC
Arrowhead Research Corporation
AstraZeneca PLC
AtheroNova Inc.
Athersys, Inc.
Avaxia Biologics, Inc.
BioRestorative Therapies, Inc.
Braasch Biotech LLC
Bridge Bioresearch Plc
Bristol-Myers Squibb Company
Calzada Limited
Carmot Therapeutics, Inc.
Chong Kun Dang Pharmaceutical Corp.
Chronos Therapeutics Limited
CrystalGenomics, Inc.
Daiichi Sankyo Company, Limited
Deltanoid Pharmaceuticals Inc.
Diabetica Limited
Digna Biotech, S.L.
DiscoveryBiomed, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Esperion Therapeutics, Inc.
Euroscreen S.A.
F. Hoffmann-La Roche Ltd.
Galapagos NV
Galenea Corp.
Genfit SA
GlaxoSmithKline plc
GTx, Inc.
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Helsinn Healthcare S.A.
High Point Pharmaceuticals, LLC
Insusense Therapeutics ApS
Intarcia Therapeutics, Inc.
Isis Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Johnson & Johnson
Kainos Medicine, Inc.
Kissei Pharmaceutical Co., Ltd.
Lead Discovery Center GmbH
LG Life Sciences, Ltd.
Mitsubishi Tanabe Pharma Corporation
Molecular Design International, Inc.
Neothetics, Inc.
NGM Biopharmaceuticals, Inc.
nLife Therapeutics, S.L.
Nordic Bioscience a/s
Novo Nordisk A/S
ObeTherapy Biotechnology
Omeros Corporation
OPKO Health, Inc.
Orbis Biosciences, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Orexigen Therapeutics, Inc.
P2D Bioscience
Pfizer Inc.
PharmaIN Corporation
Piramal Enterprises Limited
Plexxikon Inc.
Prometheon Pharma, LLC
Regulus Therapeutics Inc.
Reviva Pharmaceuticals Inc.
Rhythm Pharmaceuticals
Saniona AB
Sanofi
Shanghai Pharmaceutical Co., Ltd.
Shionogi & Co., Ltd.
Sirona Biochem Corp
Sorrento Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
Transition Therapeutics Inc.
Upsher-Smith Laboratories, Inc.
Versartis, Inc.
Verva Pharmaceuticals Limited
Vicore Pharma AB
WhanIn Pharmaceutical Co., Ltd.
X-BODY BioSciences, Inc.
Xenetic Biosciences plc
XL-protein GmbH
Zafgen Inc.
Zealand Pharma A/S
Zydus Cadila Healthcare Limited

Complete report is available @
http://www.reportstack.com/product/194303/obesity-pipeline-review-h1-2015.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604